Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.

Clin Transl OncolMay 4, 2026 (epub)
Clinical ResearchOncology (Medical)PulmonologyOpen access

Tongtong Chu, Xiuxi Li, Lijuan Shan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of the systemic inflammation response index (SIRI) in lung cancer patients. Analyzing data from 27 studies with 6195 patients, the study found that high SIRI levels were significantly associated with poorer overall survival (HR = 1.83) and progression-free survival (HR = 1.53).

Key findings

  • High SIRI levels were associated with poorer overall survival (HR = 1.83, 95% CI 1.58-2.13).
  • High SIRI levels correlated with poorer progression-free survival (HR = 1.53, 95% CI 1.31-1.79).
  • The analysis included 27 studies with a total of 6195 lung cancer patients.
  • Heterogeneity was influenced by age, region, and SIRI cutoff values.

Why it matters

Understanding the prognostic implications of SIRI can aid clinicians in risk stratification and prognosis assessment for lung cancer patients, potentially guiding treatment decisions.

Source

PubMed · PMID 42081184Free full text on PubMed Central

Published in Clin Transl Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.